HOXA9 and leukemia: This highly focused discovery strategy previously resulted in the identification of a novel compound, CCI-007, that reverted the aberrant elevated transcription of disease-driving factors HOXA9, MEIS1, and CMYC downstream of the pathogenic MLL fusion protein, thereby inducing MLL-r leukemia cell death [10].